Cytokine Mod refers to the modulation or regulation of cytokine activity in the body. Cytokines are small proteins involved in cell signaling and immune responses. Cytokine modulation therapies aim to target specific cytokines or their pathways to restore immune balance, reduce inflammation, or enhance immune responses. These therapies are used in various disease indications, including autoimmune disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, as well as certain types of cancer. According to the World Health Organization (WHO), rheumatoid arthritis affects over 23 million people in Europe and the USA combined. Psoriasis, another indication for cytokine modulation therapy, affects approximately 125 million people worldwide, with a prevalence of around 2-3% in Europe and the USA. Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, affects more than 5 million people globally. Moreover, certain types of cancer, such as melanoma and lung cancer, have been associated with dysregulated cytokine activity.
The growth drivers of the Cytokine Mod market include the increasing prevalence of autoimmune diseases, inflammatory conditions, and cancer, which are driving the demand for targeted therapies. Advancements in biotechnology and immunotherapy, as well as the expanding knowledge of cytokine signaling pathways, have paved the way for the development of novel cytokine modulation therapies. Companies such as Liminal BioSci, Alphyn Biologics, Amytrx Therap, Ashvattha Therap, Beech Tree Labs, BioNTech, Enzychem Lifesci, Evergreen Therap, Fortress, Guanhao Biotech, Japan Tobacco, and Leto Laboratories are pharmaceutical companies operating in the in this category. Moreover, many companies are coming up with new molecules in this space. For instance, Fortress is currently conducting a clinical trial of the drug CNDO-201 for the treatment of gastroentritis.
Key Developments:
- In May 2023, Dermavant Sciences released efficacy and adverse events data from the phase III ADORING 1 trial of Tapinarof in Atopic dermatitis
- In May 2023, Roivant Sciences announced its intention to file sNDA for Tapinarof to US FDA for atopic dermatitis in Q1 of 2024
Approved Cytokine Mod molecules
- Pomalidomide
- Vtama (tapinarof)
Cytokine Mod Pipeline Molecules
- Trichuris suis ova (CNDO-201)
- Fezagepras (PBI-4050)
- Mosedipimod (EC-18)
- Dendrimer N-acetyl-cysteine (OP-101)
- Thimerosal (BTL-TML)
- DTRM-555
- AB-101a
- AMTX-100 CF3
- EG-HPCP-03a
- LTC004
- PBI-4547
- SAR441000
Clinical Activity and Development of Cytokine Mod
In the Cytokine Mod space, there are very few companies, conducting more than more than 100 clinical trials in this category of drugs. For instance,
- In April 2023, Dermavant Sciences completed a phase III ADORING I trial of Tapinarof in Atopic dermatitis (In children, In adolescents, In adults, In the elderly) in USA and Canada
- In Dec 2022, Celgene Corporation presented updated pharmacodynamics data from a preclinical trial Pomalidomide in Multiple myeloma at 64th American Society of Hematology Annual Meeting and Exposition 2022 (ASH-Hem-2022)
|
Product Name |
Total Studies |
|
Trichuris suis ova (CNDO-201) |
19 |
|
Fezagepras (PBI-4050) |
9 |
|
Mosedipimod (EC-18) |
8 |
|
Dendrimer N-acetyl-cysteine (OP-101) |
3 |
Target Indication Analysis of Cytokine Mod Market
Cytokine modulation refers to the regulation or manipulation of cytokine activity in the body. Cytokines are small proteins that play crucial roles in cell signaling and immune responses. They are involved in coordinating various cellular activities, including inflammation, immune cell activation, and communication between different cells. Target indication in cytokine modulation involves identifying specific cytokines or cytokine pathways that are dysregulated or overactive in certain diseases or conditions. By targeting these specific cytokines or pathways, researchers and clinicians aim to modulate their activity to restore immune balance, reduce inflammation, or enhance immune responses. This approach holds promise for the development of novel therapies for a wide range of diseases, including autoimmune disorders, inflammatory conditions, and certain types of cancer.
Cytokine Mod Market Regional Analysis
Cytokine Mod Market
The global cytokine mod market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall US regional market analysis of Cytokine Mod in the pharmaceutical industry shows significant growth potential. The increasing prevalence of autoimmune diseases and inflammatory conditions, coupled with the rising demand for targeted therapies, is driving market expansion. The US has a robust healthcare infrastructure, a favorable regulatory environment, and a high level of research and development activities, which further propel the market growth. Additionally, the presence of key pharmaceutical companies, academic institutions, and clinical research organizations enhances the development and commercialization of cytokine modulation therapies, making the US market a highly attractive and competitive space for industry players. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for Cytokine Mods. These countries are increasingly adopting Cytokine Mods due to their efficacy and potential to improve patient outcomes. On the other hand, the Cytokine Mod market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the Cytokine Mod market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Cytokine Mod drugs are used in the management of autoimmune disorders, inflammatory conditions, and certain types of cancer.
The growth drivers of the Cytokine Mod market stem from several factors. Firstly, the growing understanding of the role of cytokines in various diseases has created opportunities for targeted interventions. This knowledge has fueled research and development efforts, leading to the discovery of novel cytokine modulation therapies. Secondly, the increasing prevalence of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, along with the rising incidence of inflammatory conditions, has created a significant demand for effective treatment options.
The major players in this space are Liminal BioSci, Alphyn Biologics, Amytrx Therap, Ashvattha Therap, Beech Tree Labs, BioNTech, Enzychem Lifesci, Evergreen Therap, Fortress, Guanhao Biotech, Japan Tobacco, and Leto Laboratories.
One of the key restraints of the cytokine modulation market is the complex and interconnected nature of cytokine signaling pathways, making it challenging to develop targeted therapies without disrupting normal immune function. Additionally, the high cost associated with cytokine modulation therapies and the need for specialized manufacturing and delivery methods pose financial and logistical challenges for widespread adoption.
- Liminal BioSci
- Alphyn Biologics
- Amytrx Therap
- Ashvattha Therap
- Beech Tree Labs
- BioNTech
- Enzychem Lifesci
- Evergreen Therap
- Fortress
- Guanhao Biotech
- Japan Tobacco
- Leto Laboratories
- Roivant
- SRAM
- Sanofi
- Zhejiang DTRM Biopharma